齐拉西酮与氟哌啶醇治疗脑血管病所致精神障碍对照研究

A control study of ziprasidone vs .haloperidol in the treatment of mental disorders due to cerebral vascular disease

目的：探讨齐拉西酮与氟哌啶醇治疗脑血管病所致精神障碍的疗效及安全性。方法将62例脑血管病所致精神障碍患者分为两组，研究组32例，对照组30例，两组在神经内科常规治疗的基础上，研究组口服齐拉西酮治疗，对照组口服氟哌啶醇治疗，观察6周。治疗前后采用简明精神病量表评定临床疗效，副反应量表评定不良反应。结果治疗6周末研究组有效率93．7％、对照组为86．7％，研究组有效率高于对照组，但差异无显著性（χ2＝0．89，P＞0．05）。两组不良反应均较轻，研究组以头痛、嗜睡多见，对照组以肌强直、便秘、口干多见。结论齐拉西酮治疗脑血管病所致精神障碍疗效显著，与氟哌啶醇相当，安全性高，但不良反应表现形式有所不同，临床上可根据不同患者选用不同的药物治疗。

Objective To explore the efficacy and safety of ziprasidone vs .haloperidol in the treatment of mental disorders due to cerebral vascular disease （MDCVD） .Methods Sixty-two MDCVD patients were divided into research group （n=32） and control group （n=30） ,on the basis of neurological routine treat-ment research group took orally ziprasidone and control did haloperidol for 6 weeks .Efficacies were as-sessed with the Brief Psychiatric Rating Scale （BPRS ） before and aftere treatment and adverse reactions with the Treatment Emergent Symptom Scale （TESS） .Results At the end of the 6th week effective rate was respectively 93 .7% in research and 86 .7% in control group ,the former was higher than the latter , but difference wasn’t significant （χ^2 =0 .89 ,P〉0 .05） .Adverse reactions of both groups were mild ,main-ly headache and hypersomnia in research and myotonia ,constipation and dry mouth in control group .Con-clusion Ziprasidone has an evident effect equivalent to haloperidol in the treatment of MDCVD and higher safety ,but manifestations of adverse reactions are somew hat different , so different pharmacotherapies should be selected according to different patients clinically .